Cumberland Pharmaceuticals, Inc. (CPIX)
Stock Price:
$3.42 USD
0.04 (1.18%)
Updated Aug 12, 2020 2:05 PM EDT - Market open
Key Info
| Market Cap |
51.85M |
| Revenue (ttm) |
47.13M |
| Net Income (ttm) |
-4.52M |
| Shares Out |
15.16M |
| EPS (ttm) |
-0.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$3.42 |
| Previous Close |
$3.38 |
| Change ($) |
0.04 |
| Change (%) |
1.18% |
| Day's Open |
3.59 |
| Day's Range |
3.39 - 3.59 |
| Day's Volume |
41,238 |
| 52-Week Range |
3.10 - 6.10 |
More Stats
| Market Cap |
51.85M |
| Enterprise Value |
46.10M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.16M |
| Float |
7.80M |
| EPS (basic) |
-0.3 |
| EPS (diluted) |
-0.30 |
| FCF / Share |
0.21 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
6.04% |
| Payout Ratio |
n/a |
| Shares Short |
80,732 |
| Short Ratio |
5.80 |
| Short % of Float |
1.02% |
| Beta |
0.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
16.56 |
| PS Ratio |
1.10 |
| PB Ratio |
1.03 |
| Revenue |
47.13M |
| Operating Income |
-5.29M |
| Net Income |
-4.52M |
| Free Cash Flow |
3.13M |
| Net Cash |
5.75M |
| Net Cash / Share |
0.38 |
| Gross Margin |
82.28% |
| Operating Margin |
-11.23% |
| Profit Margin |
-10.30% |
| FCF Margin |
6.64% |
| ROA |
-2.44% |
| ROE |
-8.08% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
9.75
Current: $3.42
High
9.75
Target: 9.75
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 47.53 | 40.74 | 41.15 | 33.03 | 33.52 | 36.90 | 32.03 | 48.85 | 51.14 | 45.88 |
| Revenue Growth | 16.67% | -0.99% | 24.6% | -1.47% | -9.17% | 15.22% | -34.44% | -4.48% | 11.48% | - |
| Gross Profit | 38.78 | 33.36 | 33.78 | 27.07 | 28.55 | 31.85 | 26.59 | 43.81 | 45.78 | 42.29 |
| Operating Income | -3.62 | -7.39 | -4.08 | -1.43 | 1.11 | 3.56 | -3.80 | 8.82 | 9.85 | 6.50 |
| Net Income | -3.54 | -6.96 | -7.98 | -0.94 | 0.73 | 2.42 | -2.10 | 5.84 | 5.66 | 2.46 |
| Shares Outstanding | 15.40 | 15.61 | 15.91 | 16.24 | 16.72 | 17.62 | 18.33 | 19.56 | 20.34 | 20.33 |
| Earnings Per Share | -0.23 | -0.45 | -0.50 | -0.06 | 0.04 | 0.14 | -0.11 | 0.30 | 0.28 | 0.12 |
| EPS Growth | - | - | - | - | -71.43% | - | - | 7.14% | 133.33% | - |
| Operating Cash Flow | 3.06 | 3.11 | -0.56 | 0.57 | 5.88 | 6.69 | 0.75 | 7.14 | 8.72 | 0.35 |
| Capital Expenditures | -1.02 | -4.28 | -1.49 | -2.13 | -2.70 | -3.26 | -7.56 | -2.54 | -0.44 | -0.77 |
| Free Cash Flow | 2.04 | -1.16 | -2.05 | -1.56 | 3.18 | 3.43 | -6.81 | 4.60 | 8.28 | -0.42 |
| Cash & Equivalents | 28.21 | 36.23 | 50.09 | 50.13 | 52.77 | 54.71 | 54.89 | 71.04 | 70.60 | 65.89 |
| Total Debt | 21.50 | 20.00 | 9.80 | 4.10 | 1.70 | - | - | 4.36 | 4.86 | 7.78 |
| Net Cash / Debt | 6.72 | 16.23 | 40.29 | 46.03 | 51.07 | 54.71 | 54.89 | 66.68 | 65.74 | 58.12 |
| Assets | 105 | 113 | 93.23 | 93.40 | 91.92 | 95.41 | 87.61 | 98.59 | 95.52 | 92.05 |
| Liabilities | 53.46 | 57.12 | 29.31 | 20.28 | 15.10 | 14.65 | 8.32 | 13.03 | 12.68 | 14.34 |
| Book Value | 51.12 | 55.84 | 64.12 | 73.25 | 76.89 | 80.76 | 79.47 | 85.70 | 82.93 | 77.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cumberland Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
94 |
| CEO |
A. J. Kazimi |
Stock Information
| Ticker Symbol |
CPIX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers - Other |
| Unique Identifier |
NASDAQ: CPIX |
| IPO Date |
August 11, 2009 |
Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.